What are the main business models in synthetic biology?
In our synthetic biology market deck, you will find everything you need to understand the market
SUMMARY
The main business models in synthetic biology are research tools, automated laboratory services, process licensing, recurring B2B biosolutions, finished biological products, and therapeutics. The strongest economics today tend to appear where biology is sold as a repeatable input rather than as a long, bespoke development project.
Recurring enzymes, microbes and other biosolutions currently provide the clearest proof that engineered biology can become a durable business. Novonesis combines broad end-market exposure with strong margins, while Codexis shows that smaller specialist products can also command unusually high gross margins once they are embedded in a customer's process.
DNA synthesis is one of the cleanest picks-and-shovels models because it gets paid for experimentation itself. Twist can benefit when researchers design and test more sequences even if most of those experiments never become successful drugs, diagnostics or products.
The horizontal foundry model has been much harder. Ginkgo and Zymergen showed that robotics, machine learning and biological engineering do not automatically create software-like operating leverage when every program still requires physical experiments, scientists and expensive laboratory infrastructure.
Autonomous labs may improve those economics by turning custom research into more standardized assays and capacity. That is a more concrete product than a broad organism-programming platform, but commercial proof is still early and the fixed-cost problem has not disappeared.
For capital-heavy industrial markets, licensing usually looks safer than owning every plant. Genomatica shows the appeal of letting chemical companies finance conventional infrastructure, while Twist and Solugen illustrate the opposite case: owning production can make sense when the manufacturing architecture itself is part of the technical moat.
Royalties are valuable when they sit on top of revenue earned today. They are much less useful when a company has to survive for years while waiting for a plant, product or drug to reach commercialization, because future milestones and royalties can contain several layers of execution risk.
Precision fermentation looks more convincing as a B2B ingredient business than as a platform for building consumer brands. Amyris demonstrated how quickly fermentation, manufacturing, inventory, retail and marketing can become too many businesses at once; Perfect Day's renewed focus on whey ingredients is a narrower bet.
Agricultural synthetic biology is already behaving like a real product category. Pivot Bio sells into an existing farmer budget, has reached nearly 20 million cumulative acres, and can benefit from seasonal repeat purchasing without needing customers to build new infrastructure first.
The broad pattern is simple: synthetic biology works best when customers reorder, production is standardized, value per unit is high, capital commitments are manageable, and the distance from scientific success to cash is short. Commodity biomanufacturing, bespoke foundries and therapeutics can still create enormous value, but they ask far more things to go right before the business gets paid.
This market map, featured in our synthetic biology market deck, highlights top companies and startups in the synthetic biology market
What do synthetic biology companies actually sell?
Synthetic biology companies currently make money in six main ways: selling research tools, selling R&D capacity, licensing biological processes, selling recurring biological ingredients, selling finished products, or developing drugs.
That distinction is more useful than grouping companies by the organisms they engineer. Twist Bioscience and Ginkgo Bioworks both help customers engineer biology, but their economics are completely different. Twist sells DNA that researchers can order again and again. Ginkgo historically took on larger biological R&D programs and is now pushing harder into automated laboratory services. Genomatica licenses processes to industrial manufacturers. Novonesis sells enzymes, microbes and other biosolutions directly into existing production workflows. Pivot Bio sells microbial crop nutrition to farmers. Senti Bio develops programmable medicines whose value depends on clinical and regulatory success.
Some companies mix several of these models. Codexis sells enzymes while also collecting R&D, licensing and milestone revenue. LanzaTech currently earns money from engineering work, research contracts, licensing and products. Perfect Day sells precision-fermented whey protein to food companies while building manufacturing capacity around that ingredient.
So when we ask whether a synthetic biology business model works, the useful question is simple: what exactly does the customer pay for?
| Business model | What customers pay for | Typical revenue | Examples | Main risk |
|---|---|---|---|---|
| Research tools | DNA, libraries, reagents, biological components | Product sales | Twist Bioscience | Price pressure and factory utilization |
| Foundry / automated lab | Experiments and biological R&D | Service and R&D fees | Ginkgo Bioworks | Expensive labs and bespoke work |
| Process licensing | Engineered strains, processes and manufacturing rights | Upfront fees, milestones, royalties | Genomatica, LanzaTech | Long project timelines |
| B2B biosolutions | Enzymes, microbes, proteins and specialty ingredients | Recurring product sales | Novonesis, Codexis, Perfect Day | Scale-up and customer qualification |
| Finished biological products | Fertilizer, chemicals, food and other end products | Product sales | Pivot Bio, Solugen | Manufacturing and distribution |
| Synthetic biology drugs | Drug candidates and approved medicines | Partnerships, milestones, royalties, drug sales | Senti Bio | Clinical failure |
Why did the “biology as software” model disappoint?
The original “biology as software” idea has disappointed financially because automating biological design does not remove the expensive physical work that comes afterward.
Ginkgo Bioworks gives us the clearest current example. Its latest quarterly revenue fell 48% year over year to $20 million as the company continued cutting and rationalizing programs. Adjusted EBITDA was negative $36 million. For every dollar of quarterly revenue, Ginkgo lost roughly $1.80 on that adjusted EBITDA measure.
Zymergen showed an even more extreme version of the problem before Ginkgo acquired it. The company had sophisticated robotics, machine learning and biological engineering, yet generated only $16.7 million of revenue in 2021 while operating at a cost base many times larger. Its technology platform was impressive. The amount customers were actually paying for it was tiny compared with the organization required to run it.
Biology simply has more friction than software. Engineers can reuse code instantly and distribute another software copy for almost nothing. A biological program can require a new organism, new assays, months of laboratory work, scale-up experiments, purification, regulatory work and a different manufacturing setup. Automation helps at several of those stages, but the rest of the process remains stubbornly physical.
Ginkgo itself is adapting to that reality today. Its newer pitch revolves much more around concrete laboratory capacity: automated assays, cloud labs, drug-discovery services and physical infrastructure that customers can rent. That is easier to understand than the old promise that a universal organism-programming platform would eventually generate software-like economics.
Biological engineering is becoming more programmable. The business economics still look much more like science and manufacturing than SaaS.
As this chart shows, and as featured in our synthetic biology market deck, search interest in gene editing has grown significantly
Is DNA synthesis the best picks-and-shovels business in synthetic biology?
DNA synthesis is currently one of the cleanest synthetic biology business models because customers pay for a standardized input every time they run another set of experiments.
Twist Bioscience's latest numbers make the case unusually well. Quarterly revenue reached a record $118.4 million, up more than 23% year over year, while gross margin reached 52.8%. It was Twist's fourteenth consecutive quarter of sequential revenue growth.
The underlying activity grew even faster in parts of the business. Twist physically shipped about 369,000 genes during the quarter, up from roughly 237,000 a year earlier. DNA Synthesis and Protein Solutions revenue increased 39% to $56.6 million. The company shipped products to around 2,650 customers.
Those numbers tell us more than a single growth rate. Twist gets paid before anyone knows whether the customer's experiment will produce a successful drug, diagnostic or engineered organism. A researcher can fail today and still place another DNA order tomorrow.
That gives DNA synthesis a useful exposure to the overall volume of biological experimentation. If AI tools allow researchers to propose ten times more protein sequences, antibodies or genetic designs, somebody still has to make and test those designs physically. Twist can benefit from that increase without correctly predicting which molecule becomes valuable.
The model has its own pressures. DNA synthesis requires factories, automation and continued cost reductions, and Twist itself still reported an $11.3 million adjusted EBITDA loss in the latest quarter. Management nevertheless continues to target adjusted EBITDA breakeven in the current quarter, while full-year revenue guidance now implies roughly 21% growth.
Among today's synthetic biology businesses, few models give us such a direct connection between more biological experimentation and more customer orders.
If you want more recent data on this point, please see our latest synthetic biology market report.
Can synthetic biology foundries make money from R&D alone?
A synthetic biology foundry built mainly around custom R&D still looks like a weak standalone model, and Ginkgo's latest strategy suggests the company has reached much the same conclusion.
The basic idea always made sense. Rather than every pharmaceutical, agriculture or chemicals company building its own automated biology lab, a specialist could build one enormous facility and share the robots, scientists and software across many customers.
The difficulty comes from utilization. A customer can cancel a program. Another program may require different equipment. Some experiments take weeks while others take months. Scientists remain on payroll when machines sit idle. Revenue therefore moves with projects while a large part of the cost base stays in place.
Ginkgo is now trying to make the model much more standardized through autonomous labs. Its Nebula facility has more than 100 robots capable of running experiments around the clock. The company says its new ADME-One drug-testing service signed 17 customers during its first six weeks, and it has won contracts to build automated laboratories for institutions including Caltech, Northwestern, the University of Maryland and Pacific Northwest National Laboratory. The latter project alone is a $47 million, 97-instrument autonomous lab.
This version is more convincing. Customers can increasingly buy a defined assay, protocol or amount of automated laboratory capacity rather than commission a broad organism-engineering project with an uncertain endpoint.
We still need commercial proof. Ginkgo's company-wide revenue remains small relative to its costs, and government-backed laboratory projects tell us little about how quickly ordinary biotech customers will move their routine experiments into cloud labs.
For now, we would separate the two ideas clearly. Bespoke biological foundries have already struggled economically. Autonomous labs may repair some of those economics by making experiments standardized and repeatable, but that newer model is still being tested.
This chart, featured in our synthetic biology market deck, illustrates yearly VC funding for synthetic biology startups
Should synthetic biology startups license their process or own the factory?
For most capital-heavy synthetic biology markets, licensing the process is the safer model; owning the factory makes sense when the manufacturing process itself is a major part of the company's advantage.
Genomatica has followed the licensing route for years. It develops biological production processes and lets established industrial companies build and operate much of the large-scale infrastructure. Novamont, for example, built a 30,000-tonne-per-year bio-BDO plant in Italy using Genomatica technology. BASF has also licensed Genomatica's renewable BDO process.
That division of labor is attractive. The synthetic biology company concentrates on organisms, fermentation and process design. A chemical company brings plant engineering, feedstock procurement, existing customers and a much larger balance sheet.
LanzaTech shows why licensing can still produce frustratingly slow revenue. Six commercial plants currently use its carbon-fermentation technology, yet its latest quarterly licensing revenue was only $0.6 million. Engineering and other services produced $3.3 million, CarbonSmart products $3.8 million and contract research another $1 million. A licensed plant can take years to finance, build, start and ramp, so the technology provider does not suddenly become huge when the first steel goes into the ground.
There are good reasons to own production in some markets. Twist's manufacturing architecture is deeply tied to its DNA synthesis advantage, so outsourcing the core production step would give away part of what makes the company special. Solugen has made a similar choice with its Bioforge approach because demonstrating its combined biological and chemical process at industrial scale is central to what it sells.
The latest Perfect Day strategy sits somewhere between the two. After several years of restructuring, the company is now focused heavily on ingredient economics and a dedicated precision-fermentation whey facility. That plant should give Perfect Day greater control over cost and supply, but it also means carrying much more industrial risk than a pure licensing company.
We prefer a simple rule: own the manufacturing when better manufacturing creates the moat. When the surrounding factory is mostly conventional infrastructure, an industrial partner's balance sheet is usually cheaper.
| Model | Capital needed from the synbio company | How it gets paid | Best fit |
|---|---|---|---|
| Own the factory | High | Product sales | Manufacturing is part of the technical advantage |
| License the process | Low to moderate | Fees, milestones and royalties | Large conventional industrial plants |
| Hybrid | Moderate | Engineering fees plus products or royalties | Company needs some control but wants partners for scale |
If you want more recent data on this point, please see our latest synthetic biology market report.
Can royalties rescue a synthetic biology platform?
Royalties can make a synthetic biology platform far more valuable, but future royalties cannot compensate for a core business that burns too much cash today.
The attraction is easy to see. Imagine a synthetic biology platform helps a customer create an ingredient that eventually sells $500 million a year. Charging only for the original R&D leaves nearly all the value with the customer. A royalty allows the platform to keep earning money once the product reaches the market.
The timing is the problem. Biological products can spend years moving through development, pilot production, customer qualification, regulation and plant construction. Some never get there.
Senti Bio's recent restructuring gives us a very concrete example of how contingent this future value can be. Rights tied to its SENTI-202 cancer program can generate up to $60 million over seven years. The structure allocates $10 million if the FDA accepts a biologics license application, another $20 million if the drug receives approval, and $30 million once worldwide sales exceed $200 million.
That $60 million headline therefore contains three separate hurdles, including regulatory approval and substantial commercial sales. Nobody should value it like $60 million of cash sitting in the bank.
Industrial synthetic biology has the same timing issue without the clinical trial. A company can engineer a strain successfully, transfer the process to a partner and still wait years for the partner to build a plant large enough to generate meaningful royalties.
The better setup combines money now with upside later. R&D fees, product sales or engineering revenue keep the company operating; milestones and royalties let it participate if the customer's product becomes large.
That combination can be excellent. Relying mainly on the future payment is much harder.
This chart, featured in our synthetic biology market deck, shows how Twist Bioscience is capturing share in synthetic biology
Are enzymes the best proven synthetic biology business?
Enzymes and other high-value biosolutions are currently the strongest proof that engineered biology can produce a large, profitable and durable business.
Novonesis makes the case at a scale few synthetic biology startups have reached. In its latest half-year results, the company reported 8% organic sales growth and a 37.7% adjusted EBITDA margin. Growth accelerated to 9% in the second quarter, and Novonesis raised its full-year organic growth outlook from 5–7% to 7–8%.
That performance has been remarkably broad. Food & Health Biosolutions grew 9% organically in the first half, while Planetary Health Biosolutions grew 7%. Developed and emerging markets both grew 8%. Novonesis is therefore selling biology across food, household care, agriculture, health, energy and industrial applications rather than depending on one fashionable end market.
Codexis gives us a smaller but very useful comparison. Its latest quarter produced $14.9 million of total revenue, of which $13.2 million came from products. Product revenue jumped 79% year over year, and product gross margin reached 73%.
The economics work because an enzyme can be cheap relative to the value it creates. A tiny amount of biological catalyst may improve manufacturing yield, replace a harsher chemical step, lower energy consumption or create a product that is difficult to make another way. Customers can therefore save much more money than they spend on the enzyme.
Repeat purchasing makes the model even better. Once an enzyme or microbial solution has been validated inside a factory, food process or household product, the customer needs more whenever it produces another batch.
There is far less storytelling in this part of synthetic biology because the economic case is already visible in the numbers. Biology becomes particularly attractive when a small amount of engineered material creates a large amount of customer value.
If you want more recent data on this point, please see our latest synthetic biology market report.
Does precision fermentation work better as an ingredient business?
Precision fermentation currently looks much stronger as a B2B ingredient business than as a startup trying to build its own consumer brands at the same time.
Amyris remains the clearest warning. The company had genuine fermentation technology and successfully brought fermentation-derived ingredients into commercial products. By 2022, Amyris was also running an increasingly complicated collection of consumer brands. It generated about $270 million of total annual revenue and still lost roughly $543 million. It entered Chapter 11 the following year.
The problem was the number of expensive things Amyris was trying to do together. Biological R&D had to work. Fermentation had to scale. Manufacturing had to run efficiently. Ingredients needed customers. The company then added inventory, advertising, e-commerce, retail distribution and consumer-brand management.
Perfect Day has moved in the opposite direction. The company sold its consumer-goods arm in 2023 and has increasingly concentrated on ProFerm, its precision-fermented whey protein. Its current partner list includes Unilever, Nestlé, Bel, Mars and Myprotein, allowing established food companies to handle much of the branding and distribution.
A recent update from Perfect Day is especially revealing. After operating quietly for roughly two years to work on cost and manufacturing, the company is preparing a dedicated large-scale precision-fermentation facility and putting much more emphasis on supplying whey as an ingredient. That is a very different strategy from launching another animal-free ice-cream brand.
The direction is sensible. Fermentation startups already face one of the hardest industrial scale-up problems in food. Asking the same team to out-market Nestlé or Unilever adds an unrelated problem on top.
The B2B ingredient model leaves plenty of difficulty. Perfect Day still has to manufacture protein cheaply enough to compete and keep its plant busy. But at least the company can concentrate its resources on the part where its technology gives it an advantage.
This chart, featured in our synthetic biology market deck, illustrates yearly funding for synthetic biology startups
Can synthetic biology really make money on commodity chemicals?
Synthetic biology can make money in chemicals, but low-priced commodity molecules remain one of the toughest places to build the business because biology eventually has to compete with decades of brutally optimized chemical manufacturing.
Solugen shows what reaching that stage looks like. Its Bioforge process combines engineered enzymes with chemical catalysis to manufacture chemicals from plant-derived feedstocks. The company's next large site in Marshall is being integrated with an ADM corn-processing facility, giving it direct access to dextrose feedstock.
The scale of the project tells us what industrial biology eventually becomes. The US Department of Energy considered a federal loan guarantee of up to $213.6 million for the Marshall project. Once a synthetic biology company starts making large volumes of chemicals, tanks, utilities, feedstocks, purification equipment and financing become just as important as gene editing.
LanzaTech has reached commercial plants through another route. Its technology converts waste carbon into products through gas fermentation, and six commercial plants are now operating. Yet the company's latest quarter produced only $9 million of revenue and an adjusted EBITDA loss of $7.6 million.
That gap between physical deployment and financial scale is important. A working industrial plant proves that the biology can leave the laboratory. It does not prove that the technology owner will earn high margins.
Specialty chemicals have an easier equation. A molecule selling for $50 or $100 per kilogram can absorb fermentation, purification and capital costs that would destroy the economics of something selling for $1 per kilogram.
For bulk chemicals, we would want to see a real cost advantage somewhere: cheaper feedstock, fewer processing steps, lower energy use, better yield, simpler purification, useful co-products or customers willing to pay more for the lower-carbon product. Sustainability can help close the gap. It rarely replaces the need for competitive economics.
Is the hybrid model becoming the default in synthetic biology?
Yes, hybrid business models are becoming normal in synthetic biology because the same biological technology can generate R&D fees, product sales, licenses and royalties at different stages.
Codexis is a good example of a focused hybrid. Its latest quarterly product revenue grew to $13.2 million, while research and development revenue supplied the rest of its $14.9 million total. That R&D category can include research services, licenses, milestones and royalties. The core capability remains enzyme engineering even though customers pay Codexis in several different ways.
LanzaTech also earns several types of revenue around the same carbon-fermentation technology. Its latest quarter included $3.3 million from engineering and other services, $3.8 million from CarbonSmart products, $1 million from contract research, $0.6 million from licensing and a smaller amount from joint-development agreements.
There is a useful difference between that kind of hybrid and the model Amyris eventually created. Codexis can add a license or an R&D contract without learning how to run a cosmetics brand. LanzaTech can provide engineering work and later collect technology-related revenue from the same industrial project. The activities reinforce the original technical capability.
Synthetic biology companies get into trouble when “multiple revenue streams” becomes a polite way of saying the original revenue stream never became large enough.
The version we like is much narrower: get paid during development, get paid again when the product launches, and retain some upside if it becomes successful. That gives the company several chances to earn money from the same piece of biology without forcing it into unrelated businesses.
This chart, featured in our synthetic biology market deck, compares the main business model options for synthetic biology platforms
Is agricultural synthetic biology already a real product business?
Agricultural synthetic biology is already producing real repeat-purchase products, and Pivot Bio is one of the clearest examples of engineered microbes moving well beyond pilot projects.
Pivot Bio engineers microbes that supply nitrogen to crops. Its products have now been used across nearly 20 million acres in North America, up from around 15 million cumulative acres cited in earlier company materials. Thousands of farmers have used the technology across crops including corn, wheat, cotton and other cereals.
The business is easy to understand from the farmer's side. A farmer already has a nitrogen budget. Pivot Bio is trying to capture part of that existing spending by replacing some conventional fertilizer with microbial nitrogen.
The company has also started behaving much more like a mature agricultural-input supplier. Its current multi-year pricing program lets qualifying farmers lock in product pricing through the 2028 growing season, with minimum acreage commitments. That creates a more predictable relationship than selling a one-off biological experiment.
Another interesting data point comes from Pivot's N-OVATOR program. In 2024, 1.4 million acres were enrolled by 1,235 farmers, with 48.6 million pounds of synthetic fertilizer replacement documented. The program paid farmers $4.5 million for the associated environmental benefits, equal to about $5 per acre and nearly 30% of participating growers' Pivot Bio product cost.
That adds a second economic layer to the product. Farmers can potentially combine the agronomic value of microbial nitrogen with payments linked to avoided emissions.
We still need to separate acreage from proven profitability because Pivot Bio is private and publishes little financial data. But commercial adoption is no longer the main uncertainty. The more interesting questions today are how much farmers reorder, how much nitrogen the products can consistently replace, and whether the economics remain attractive without unusually high fertilizer prices.
Do synthetic biology drug companies really have a different business model?
Synthetic biology drug companies mostly behave like ordinary biotech companies once their engineered biology becomes a clinical drug candidate.
Senti Bio illustrates this neatly. Its technology uses genetic circuits to make cells respond differently to biological inputs, which is classic synthetic biology. The company's finances, however, depend on clinical trials, regulatory decisions, financing and eventual drug sales.
Its recent corporate restructuring makes the split especially visible. Senti moved the gene-circuit pipeline containing SENTI-202 into a transaction that gives existing holders rights to up to $60 million of future milestone payments, while the remaining company plans to focus on another controllable genetic-medicine platform.
The value of SENTI-202 now depends on events familiar to any biotech investor: filing a biologics license application, getting FDA approval and reaching meaningful product sales.
Synthetic biology can still create the technical advantage. Logic-gated cells, controllable gene expression and programmable therapies may eventually produce drugs that conventional biotechnology cannot easily make.
From a business-model perspective, though, those companies belong in the therapeutics bucket. Their upside can be enormous, but their economics are driven much more by the probability of clinical success than by the efficiency of a horizontal synthetic biology platform.
That distinction prevents a common analytical mistake. A synthetic biology drug becoming successful would prove that synthetic biology can create valuable medicines. It would tell us much less about whether foundries, DNA synthesis or industrial fermentation are good businesses.
This chart, featured in our synthetic biology market deck, illustrates the share of revenue generated by each customer segment in the synthetic biology market
Should synthetic biology companies sell the final product themselves?
Synthetic biology companies should sell the final product when doing so captures a valuable existing customer budget without forcing the company to build an entirely new commercial machine.
Pivot Bio fits that logic well. Farmers already purchase nitrogen products, so selling microbial nitrogen directly gives Pivot access to the full product revenue while keeping the commercial behavior familiar to the customer.
Solugen has similar reasons to sell chemicals rather than collect only a small technology royalty. If its Bioforge process genuinely produces chemicals with better economics, owning more of the product margin could create much more value.
Consumer goods create a much tougher jump. Amyris moved from fermentation and ingredients into beauty brands, which meant competing for consumers, retail shelf space and advertising attention. Those skills had little overlap with engineering yeast or running fermentation.
Perfect Day's move back toward supplying whey protein gives us the opposite example. Unilever can decide how to market ice cream. Mars can sell chocolate. Perfect Day can spend more of its capital solving fermentation cost and protein supply.
The practical test is how far the company has to travel from the biological breakthrough to the customer. Selling an engineered crop input to farmers or an enzyme to factories can be a manageable extension of the technology. Building an international consumer brand creates a second company inside the first one.
Vertical integration can produce more revenue, but revenue capture alone is a poor reason to integrate. We would only keep moving downstream while each extra step strengthens the original advantage.
If you want more recent data on this point, please see our latest synthetic biology market report.
What makes a synthetic biology business model actually work?
The synthetic biology businesses working best today tend to combine repeat purchases, high value per unit, standardized production and relatively few hurdles between technical success and getting paid.
Twist gets another order whenever a customer needs more DNA. Novonesis sells enzymes and microbes that customers consume repeatedly in their own products and processes. Codexis can supply another batch of an enzyme once its customer's manufacturing process is established. Pivot Bio has another sales opportunity every planting season.
Compare that with a company developing a biological process for a new industrial plant. First the strain must work. Then fermentation must scale. Then the process must reach the right cost. Then the customer needs financing. Then somebody builds the plant. Then the plant ramps. Only after all of that can large recurring product or royalty revenue appear.
The distance between scientific success and cash is therefore one of the most useful things we can measure.
Value density also matters enormously. Codexis can report a 73% product gross margin because its enzymes perform specialized jobs inside high-value manufacturing processes. Commodity fermentation faces a completely different calculation because a few cents per kilogram can decide whether the plant makes money.
Standardization creates another big divide. Twist can process huge numbers of different DNA sequences through the same manufacturing system. Novonesis can sell an established enzyme to many customers. A bespoke biological-development project may need scientists to redesign the workflow for every client.
Capital then magnifies everything. If reaching commercial scale requires a $200 million plant before the company has proven demand, one forecasting mistake can become fatal. A licensing company can survive the same mistake much more easily.
When we compare synthetic biology companies, these variables tell us far more than the sophistication of the underlying science: how often customers reorder, how standardized the work is, how much value each unit creates, how much capital has to be committed and how many things still need to go right before cash arrives.
This chart, featured in our synthetic biology market deck, shows how gene therapy technology has evolved over time
Which synthetic biology business models look strongest today?
The strongest synthetic biology business models today are recurring B2B biosolutions and research tools, followed by focused product businesses and capital-light licensing; bespoke foundries and commodity biomanufacturing remain much harder.
Our highest-confidence case is biosolutions. Novonesis has just reported 8% first-half organic growth, a 37.7% adjusted EBITDA margin and an increased full-year growth outlook. Codexis is much smaller, but its latest 73% product gross margin points in the same direction. High-value enzymes and microbes can become extremely attractive when customers buy them repeatedly and the biology represents only a small part of the customer's total cost.
DNA synthesis belongs close to the top. Twist is growing revenue above 20%, has pushed gross margin above 50% and keeps increasing the physical volume of genes shipped. The model benefits directly from more biological experimentation.
Agricultural products also look much more credible now than a few years ago. Pivot Bio's nearly 20 million cumulative acres show that engineered microbes can become normal farm inputs when they fit an existing purchasing decision.
Licensing remains a strong choice for capital-heavy markets. Genomatica's model avoids asking a biology startup to finance every industrial plant. The downside is patience: industrial projects can take years before meaningful royalties arrive.
Precision-fermented ingredients are moving in a more sensible direction too. Perfect Day's retreat from consumer-brand building and renewed focus on cost, manufacturing and B2B whey supply looks much closer to the economics we would want from a fermentation company.
Autonomous laboratories deserve a separate “promising but unproven” label. Ginkgo has more than 100 robots operating in Nebula, early customers for standardized services and several major institutional projects. We still need to see those assets produce a much larger recurring commercial revenue base.
The broad bespoke-foundry model ranks near the bottom based on the evidence so far. Ginkgo's restructuring and Zymergen's collapse showed how expensive these platforms can become when customer revenue fails to scale with the laboratory infrastructure.
Commodity chemicals can eventually be enormous, but we would rank them among the hardest businesses to execute. Solugen and LanzaTech have both moved biology into real industrial infrastructure. The remaining test is whether those deployments can produce returns that justify the capital and time required.
Synthetic biology therefore has several viable business models today, but the winning pattern is becoming clearer. The companies doing best sell something concrete, repeatable and valuable while keeping the number of additional problems they must solve under control. Biology can be extremely sophisticated inside the product. The way the customer pays for it usually needs to be much simpler.
| Current business model | Our view today | Why |
|---|---|---|
| Enzymes and recurring biosolutions | Strongest proven model | Repeat purchases, high value density, strong margins |
| DNA synthesis and research tools | Strong | Standardized demand rises with experimentation |
| Agricultural biological products | Increasingly proven | Existing customer budget and repeat seasonal demand |
| Process licensing | Attractive | Limits capital exposure in heavy industry |
| B2B precision-fermented ingredients | Promising | Better focus than building consumer brands |
| Hybrid product + licensing + R&D | Strong when focused | Monetizes the same technology several ways |
| Autonomous labs | Promising but early | Better standardization, little proof of mature economics yet |
| Synthetic biology therapeutics | High-risk biotech model | Huge upside tied to clinical success |
| Commodity biomanufacturing | Difficult | Thin margins and major industrial capex |
| Bespoke horizontal foundries | Weakest evidence so far | High fixed costs and difficult operating leverage |
If you want more recent data on this point, please see our latest synthetic biology market report.
OUR METHODOLOGY
This analysis asks which synthetic biology business models actually work by comparing what customers pay for, how often they pay, how standardized the work is, how much capital is required to reach scale, where margins appear, and how far each model sits from recurring cash generation. That framework lets us compare businesses that all use engineered biology but have very different economics.
For each model, we prioritized the freshest relevant evidence available: recent financial results, operating metrics, customer adoption, commercial deployments, manufacturing progress, transactions and changes in company strategy. We used margins to test value capture, order and adoption data to test repeatability, plant deployments to establish industrial execution, and strategic shifts to see how companies themselves are adapting their models.
No single metric determines the ranking. Revenue growth without attractive economics can mislead; a commercial plant does not automatically prove good returns; high margins at small scale do not establish durability; and a future milestone is different from cash generated today. The final labels are therefore a synthesis of several pieces of evidence rather than the output of a mechanical scoring formula.
Models moved higher when the evidence repeatedly pointed toward repeat purchasing, standardization, strong value capture, manageable capital requirements and a relatively short path from technical success to revenue. They moved lower when high fixed costs, long commercialization chains, difficult utilization, heavy capital requirements or several additional conditions stood between successful biology and getting paid.
Key sources used for this analysis include Twist Bioscience's fiscal Q3 2026 results, Ginkgo Bioworks' Q2 2026 results and Q2 2026 Form 10-Q, Zymergen's 2021 Form 10-K, Novonesis' H1 2026 results, Codexis' Q2 2026 results, LanzaTech's Q2 2026 results, the U.S. Department of Energy review of Solugen's Marshall project, Amyris' 2022 Annual Report, Perfect Day's ProFerm materials, Pivot Bio's 2024 Impact Report, and Senti Bio's SEC filing on the SENTI-202 milestone structure.
In our synthetic biology market deck, we identify pain points entrepreneurs should prioritize
Related blog posts
- Synthetic Biology: who are the top startups?
- How large is the synthetic biology market today?
- What does the synthetic biology startup landscape look like today?
